Karyopharm Therapeutics Inc.
KPTI
$5.40
$0.459.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 145.24M | 148.44M | 145.67M | 140.46M | 146.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 145.24M | 148.44M | 145.67M | 140.46M | 146.03M |
| Cost of Revenue | 6.01M | 16.72M | 15.75M | 8.59M | 4.94M |
| Gross Profit | 139.23M | 131.72M | 129.92M | 131.87M | 141.09M |
| SG&A Expenses | 115.44M | 118.94M | 122.11M | 125.52M | 131.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 264.68M | 274.41M | 276.62M | 272.86M | 275.57M |
| Operating Income | -119.44M | -125.97M | -130.95M | -132.40M | -129.54M |
| Income Before Tax | -76.37M | -87.18M | -89.63M | -146.00M | -142.78M |
| Income Tax Expenses | 57.00K | 296.00K | 280.00K | 340.00K | 323.00K |
| Earnings from Continuing Operations | -76.42 | -87.48 | -89.91 | -146.34 | -143.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.42M | -87.48M | -89.91M | -146.34M | -143.10M |
| EBIT | -119.44M | -125.97M | -130.95M | -132.40M | -129.54M |
| EBITDA | -119.10M | -125.63M | -130.61M | -132.08M | -129.01M |
| EPS Basic | -9.39 | -11.19 | -11.86 | -18.41 | -18.79 |
| Normalized Basic EPS | -9.35 | -10.45 | -10.88 | -11.93 | -11.72 |
| EPS Diluted | -14.70 | -16.47 | -17.10 | -18.48 | -18.85 |
| Normalized Diluted EPS | -9.00 | -10.10 | -10.53 | -11.93 | -11.72 |
| Average Basic Shares Outstanding | 32.49M | 31.75M | 31.04M | 30.59M | 30.46M |
| Average Diluted Shares Outstanding | 34.72M | 33.98M | 33.27M | 30.59M | 30.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |